Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Docta Complutense
Publication Artículo científico (JournalArticle)

Prospects for γ-ray observations of the Perseus galaxy cluster with the Cherenkov Telescope Array

  • Alvarez-Crespo, N.
  • Barrio Uña, Juan Abel
  • Contreras González, José Luis
  • Láinez, M.
  • López Moya, Marcos
  • Martinez, O.
  • Mas-Aguilar, A.
  • Miener, Tjark
  • Miranda, J.M.
  • Morcuende Parrilla, Daniel
  • Nieto Castaño, Daniel
  • Rosado Vélez, Jaime
  • Sinha, Atreyee
  • Tejedor Álvarez, Luis Ángel
  • Zamanillo, V.M.
Galaxy clusters are expected to be both dark matter (DM) reservoirs and storage rooms for the cosmic-ray protons (CRp) that accumulate along the cluster’s formation history. Accordingly, they are excellent targets to search for signals of DM annihilation and decay at γ-ray energies and are predicted to be sources of large-scale γ-ray emission due to hadronic interactions in the intracluster medium (ICM). In this paper, we estimate the sensitivity of the Cherenkov Telescope Array (CTA) to detect diffuse γ-ray emission from the Perseus galaxy cluster. We first perform a detailed spatial and spectral modelling of the expected signal for both the DM and the CRp components. For each case, we compute the expected CTA sensitivity accounting for the CTA instrument response functions. The CTA observing strategy of the Perseus cluster is also discussed. In the absence of a diffuse signal (non-detection), CTA should constrain the CRp to thermal energy ratio X500 within the characteristic radius R500 down to about X500 < 3 × 10−3, for a spatial CRp distribution that follows the thermal gas and a CRp spectral index αCRp = 2.3. Under the optimistic assumption of a pure hadronic origin of the Perseus radio mini-halo and depending on the assumed magnetic field profile, CTA should measure αCRp down to about ∆αCRp ≃ 0.1 and the CRp spatial distribution with 10% precision, respectively. Regarding DM, CTA should improve the current ground-based γ-ray DM limits from clusters observations on the velocity-averaged annihilation cross-section by a factor of up to ∼ 5, depending on the modelling of DM halo substructure. In the case of decay of DM particles, CTA will explore a new region of the parameter space, reaching models with τχ > 1027 s for DM masses above 1 TeV. These constraints will provide unprecedented sensitivity to the physics of both CRp acceleration and transport at cluster scale and to TeV DM particle models, especially in the decay scenario.
Repisalud
Publication Artículo científico (JournalArticle)

A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants.

  • Earl, Julie
  • Galindo-Pumariño, Cristina
  • Encinas, Jessica
  • Barreto, Emma
  • Castillo, Maria E
  • Pachón, Vanessa
  • Ferreiro, Reyes
  • Rodríguez-Garrote, Mercedes
  • González-Martínez, Silvia
  • Ramon Y Cajal, Teresa
  • Diaz, Luis Robles
  • Chirivella-Gonzalez, Isabel
  • Rodriguez, Montse
  • de Castro, Eva Martínez
  • García-Seisdedos, David
  • Muñoz, Gloria
  • Rosa, Juan Manuel Rosa
  • Marquez, Mirari
  • Carrato, Alfredo
  • Malats, Nuria
The 5-year survival rate of patients with pancreatic ductal adenocarcinoma (PDAC) is around 5% due to the fact that the majority of patients present with advanced disease that is treatment resistant. Familial pancreatic cancer (FPC) is a rare disorder that is defined as a family with at least two affected first degree relatives, with an estimated incidence of 4%-10%. The genetic basis is unknown in the majority of families although around 10%-13% of families carry germline mutations in known genes associated with hereditary cancer and pancreatitis syndromes. Panel sequencing was performed of 35 genes associated with hereditary cancer in 43 PDAC cases from families with an apparent hereditary pancreatic cancer syndrome. Pathogenic variants were identified in 19% (5/26) of PDAC cases from pure FPC families in the genes MLH1, CDKN2A, POLQ and FANCM. Low frequency potentially pathogenic VUS were also identified in 35% (9/26) of PDAC cases from FPC families in the genes FANCC, MLH1, PMS2, CFTR, APC and MUTYH. Furthermore, an important proportion of PDAC cases harboured more than one pathogenic, likely pathogenic or potentially pathogenic VUS, highlighting the multigene phenotype of FPC. The genetic basis of familial or hereditary pancreatic cancer can be explained in 21% of families by previously described hereditary cancer genes. Low frequency variants in other DNA repair genes are also present in 35% of families which may contribute to the risk of pancreatic cancer development. This study was funded by the Instituto de Salud Carlos III (Plan Estatal de I + D + i 2013-2016): ISCIII (PI09/02221, PI12/01635, PI15/02101 and PI18/1034) and co-financed by the European Development Regional Fund ''A way to achieve Europe'' (ERDF), the Biomedical Research Network in Cancer: CIBERONC (CB16/12/00446), Red Temática de investigación cooperativa en cáncer: RTICC (RD12/0036/0073) and La Asociación Española contra el Cáncer: AECC (Grupos Coordinados Estables 2016).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Endothelial cell activation on 3D-matrices derived from PDGF-BB-stimulated fibroblasts is mediated by Snail1

  • Herrera, Alberto
  • Herrera, Mercedes
  • Guerra-Perez, Natalia
  • Galindo-Pumariño, Cristina
  • Larriba, María Jesús
  • García-Barberán, Vanesa
  • Gil, Beatriz
  • Giménez-Moyano, Sara
  • Ferreiro-Monteagudo, Reyes
  • Veguillas, Pilar
  • Candia, Antonio
  • Peña, Raúl|||0000-0002-1650-9720
  • Pinto, Jesús
  • García-Bermejo, Mª Laura
  • Muñoz, Alberto|||0000-0003-3890-4251
  • Garcia de Herreros, Antonio|||0000-0001-5270-0808
  • Bonilla, Félix
  • Carrato, Alfredo|||0000-0001-7749-8140
  • Peña, Cristina
Carcinomas, such as colon cancer, initiate their invasion by rescuing the innate plasticity of both epithelial cells and stromal cells. Although Snail is a transcriptional factor involved in the Epithelial-Mesenchymal Transition, in recent years, many studies have also identified the major role of Snail in the activation of Cancer-Associated Fibroblast (CAF) cells and the remodeling of the extracellular matrix. In CAFs, Platelet-derived growth factor (PDGF) receptor signaling is a major functional determinant. High expression of both SNAI1 and PDGF receptors is associated with poor prognosis in cancer patients, but the mechanism(s) that underlie these connections are not understood. In this study, we demonstrate that PDGF-activated fibroblasts stimulate extracellular matrix (ECM) fiber remodeling and deposition. Furthermore, we describe how SNAI1, through the FAK pathway, is a necessary factor for ECM fiber organization. The parallel-oriented fibers are used by endothelial cells as "tracks", facilitating their activation and the creation of tubular structures mimicking in vivo capillary formation. Accordingly, Snail1 expression in fibroblasts was required for the co-adjuvant effect of these cells on matrix remodeling and neoangiogenesis when co-xenografted in nude mice. Finally, in tumor samples from colorectal cancer patients a direct association between stromal SNAI1 expression and the endothelial marker CD34 was observed. In summary, our results advance the understanding of PDGF/SNAI1-activated CAFs in matrix remodeling and angiogenesis stimulation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Increased plasma levels of galectin-1 in pancreatic cancer, potential use as biomarker

  • Martínez Bosch, Neus|||0000-0003-3596-0039
  • Barranco, Luis E.
  • Orozco, Carlos A.
  • Moreno Martínez-Losa, Mireia|||0000-0002-4365-4341
  • Visa, Laura|||0000-0002-3409-8857
  • Iglesias, Mar|||0000-0002-2274-4671
  • Oldfield, Lucy
  • Neoptolemos, John P.|||0000-0002-6201-7399
  • Greenhalf, William
  • Earl, Julie
  • Carrato, Alfredo|||0000-0001-7749-8140
  • Costello, Eithne
  • Navarro, Pilar|||0000-0003-4314-4584
Pancreatic ductal adenocarcinoma (PDA) is the most frequent type of pancreatic cancer and one of the deadliest diseases overall. New biomarkers are urgently needed to allow early diagnosis, one of the only factors that currently improves prognosis. Here we analyzed whether the detection of circulating galectin-1 (Gal-1), a soluble carbohydrate-binding protein overexpressed in PDA tissue samples, can be used as a biomarker for PDA. Gal-1 levels were determined by ELISA in plasma from healthy controls and patients diagnosed with PDA, using three independent cohorts. Patients with chronic pancreatitis (CP) were also included in the study to analyze the potential of Gal-1 to discriminate between cancer and inflammatory process. Plasma Gal-1 levels were significantly increased in patients with PDA as compared to controls in all three cohorts. Gal-1 sensitivity and specificity values were similar to that of the CA19-9 biomarker (the only FDA-approved blood test biomarker for PDA), and the combination of Gal-1 and CA19-9 significantly improved their individual discriminatory powers. Moreover, high levels of Gal-1 were associated with lower survival in patients with non-resected tumors. Collectively, our data indicate a strong potential of using circulating Gal-1 levels as a biomarker for detection and prognostics of patients with PDA.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants

  • Earl, Julie
  • Galindo-Pumariño, Cristina
  • Encinas, Jessica
  • Barreto, Emma|||0000-0002-0410-2261
  • Castillo, Maria E.
  • Pachón, Vanessa
  • Ferreiro, Reyes
  • Rodríguez Garrote, Mercedes|||0000-0003-0486-6760
  • González-Martínez, Silvia
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Diaz, Luis Robles
  • Chirivella-Gonzalez, Isabel
  • Rodriguez, Montse
  • Martínez de Castro, Eva|||0000-0002-5772-0741
  • García-Seisdedos, David
  • Muñoz, Gloria
  • Rosa, Juan Manuel Rosa
  • Marquez, Mirari
  • Malats, Núria|||0000-0003-2538-3784
  • Carrato, Alfredo|||0000-0001-7749-8140
The 5-year survival rate of patients with pancreatic ductal adenocarcinoma (PDAC) is around 5% due to the fact that the majority of patients present with advanced disease that is treatment resistant. Familial pancreatic cancer (FPC) is a rare disorder that is defined as a family with at least two affected first degree relatives, with an estimated incidence of 4%-10%. The genetic basis is unknown in the majority of families although around 10%-13% of families carry germline mutations in known genes associated with hereditary cancer and pancreatitis syndromes. Panel sequencing was performed of 35 genes associated with hereditary cancer in 43 PDAC cases from families with an apparent hereditary pancreatic cancer syndrome. Pathogenic variants were identified in 19% (5/26) of PDAC cases from pure FPC families in the genes MLH1, CDKN2A, POLQ and FANCM. Low frequency potentially pathogenic VUS were also identified in 35% (9/26) of PDAC cases from FPC families in the genes FANCC, MLH1, PMS2, CFTR, APC and MUTYH. Furthermore, an important proportion of PDAC cases harboured more than one pathogenic, likely pathogenic or potentially pathogenic VUS, highlighting the multigene phenotype of FPC. The genetic basis of familial or hereditary pancreatic cancer can be explained in 21% of families by previously described hereditary cancer genes. Low frequency variants in other DNA repair genes are also present in 35% of families which may contribute to the risk of pancreatic cancer development. This study was funded by the Instituto de Salud Carlos III (Plan Estatal de I + D + i 2013-2016): ISCIII (PI09/02221, PI12/01635, PI15/02101 and PI18/1034) and co-financed by the European Development Regional Fund ''A way to achieve Europe'' (ERDF), the Biomedical Research Network in Cancer: CIBERONC (CB16/12/00446), Red Temática de investigación cooperativa en cáncer: RTICC (RD12/0036/0073) and La Asociación Española contra el Cáncer: AECC (Grupos Coordinados Estables 2016).